Related Experiment Video
Updated: Feb 15, 2026
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records
Mar Pujades-Rodriguez1,2, Oliver P Guttmann3, Arturo Gonzalez-Izquierdo2
1Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.
Insights
Patients with hypertrophic cardiomyopathy (HCM) face significantly higher risks of serious cardiovascular events, including arrhythmias, cardiac arrest, and heart failure. This highlights a major unmet need for improved prevention strategies and better clinical trial designs in HCM.
Area of Science:
- Cardiology
- Clinical Epidemiology
- Public Health
Background:
- Hypertrophic cardiomyopathy (HCM) is a complex cardiac condition with potential for severe outcomes.
- Understanding the full spectrum of clinical needs and risks in HCM patients is crucial for effective management and research.
- Existing data may not fully capture the long-term risks and unmet needs in unselected HCM populations.
Purpose of the Study:
- To evaluate the unmet clinical needs in unselected hypertrophic cardiomyopathy (HCM) patients.
- To determine the risk of subsequent cardiovascular disease and safety endpoints in HCM.
- To provide clinically relevant estimates for designing future clinical trials in rare cardiovascular diseases.
Main Methods:
- A population-based cohort study using linked electronic health records (CALIBER) in England (1997-2010).
- Identification of HCM patients and matching with general population controls.
- Random-effects Poisson models were employed to assess associations between HCM and various endpoints.
Main Results:
- HCM patients demonstrated substantially elevated risks for ventricular arrhythmia (IRR=23.53), cardiac arrest/sudden cardiac death (IRR=6.33), heart failure (IRR=4.31), and atrial fibrillation (IRR=3.80).
- Increased incidence of myocardial infarction (IRR=1.90) and coronary revascularization (IRR=2.32) were observed in HCM patients.
- Absolute 3-year risks included 8.8% for cardiovascular death/heart failure and 8.4% for cardiovascular death/stroke/myocardial infarction.
Conclusions:
- Significant unmet clinical needs exist in the hypertrophic cardiomyopathy population, necessitating enhanced cardiovascular prevention strategies.
- The study underscores the utility of national electronic health records for identifying outcomes in rare diseases.
- Findings provide essential efficacy and safety endpoint estimates crucial for the design of clinical trials in HCM.
Introduction:
To evaluate unmet clinical need in unselected hypertrophic cardiomyopathy (HCM) patients to determine the risk of a wide range of subsequent cardiovascular disease endpoints and safety endpoints relevant for trial design.
Methods:
Population based cohort (CALIBER, linked primary care, hospital and mortality records in England, period 1997-2010), all people diagnosed with HCM were identified and matched by age, sex and general practice with ten randomly selected people without HCM. Random-effects Poisson models were used to assess the associations between HCM and cardiovascular diseases and bleeding.
Results:
Among 3,290,455 eligible people a diagnosis of hypertrophic cardiomyopathy was found in 4 per 10,000. Forty-one percent of the 1,160 individuals with hypertrophic cardiomyopathy were women and the median age was 57 years. The median follow-up was 4.0 years. Compared to general population controls, people with HCM had higher risk of ventricular arrhythmia (incidence rate ratio = 23.53, [95% confidence interval 12.67-43.72]), cardiac arrest or sudden cardiac death (6.33 [3.69-10.85]), heart failure (4.31, [3.30-5.62]), and atrial fibrillation (3.80 [3.04-4.75]). HCM was also associated with a higher incidence of myocardial infarction ([MI] 1.90 [1.27-2.84]) and coronary revascularisation (2.32 [1.46-3.69]).The absolute Kaplan-Meier risks at 3 years were 8.8% for the composite endpoint of cardiovascular death or heart failure, 8.4% for the composite of cardiovascular death, stroke or myocardial infarction, and 1.5% for major bleeding.
Conclusions:
Our study identified major unmet need in HCM and highlighted the importance of implementing improved cardiovascular prevention strategies to increase life-expectancy of the contemporary HCM population. They also show that national electronic health records provide an effective method for identifying outcomes and clinically relevant estimates of composite efficacy and safety endpoints essential for trial design in rare diseases.
More Related Videos
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:11Purpose of Health Records I
Here's a breakdown of how health records serve these purposes:
01:19Purpose of Health Records II
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
01:26National Nursing Organizations I